Literature DB >> 19075681

Therapeutic antibodies and derivatives: from the bench to the clinic.

A Beck, T Wurch, N Corvaïa.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 19075681     DOI： 10.2174/138920108786786420

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN： 1389-2010            Impact factor:   2.837


× No keyword cloud information.
  16 in total

1.  Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.

Authors:  Hongwei Xie; Asish Chakraborty; Joomi Ahn; Ying Qing Yu; Deepalakshmi P Dakshinamoorthy; Martin Gilar; Weibin Chen; St John Skilton; Jeffery R Mazzeo
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 2.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

3.  4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.

Authors:  Alain Beck; Sherif Hanala; Janice M Reichert
Journal:  MAbs       Date:  2009-03-20       Impact factor: 5.857

4.  European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.

Authors:  Janice M Reichert; Alain Beck; Harish Iyer
Journal:  MAbs       Date:  2009-09-25       Impact factor: 5.857

5.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 6.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

7.  Targeted cancer therapies, part 2 #277.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  J Palliat Med       Date:  2014-02-14       Impact factor: 2.947

Review 8.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

Review 9.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.

Authors:  Timo Rath; Kristi Baker; Jennifer A Dumont; Robert T Peters; Haiyan Jiang; Shuo-Wang Qiao; Wayne I Lencer; Glenn F Pierce; Richard S Blumberg
Journal:  Crit Rev Biotechnol       Date:  2013-10-24       Impact factor: 8.429

Review 10.  Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.

Authors:  Feng Wen; Qiu Li
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.